Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | ME2 | P23368 | 2/20 | 0.41 |
| ▸ | ME1 | P48163 | 2/20 | 0.41 |
| ▸ | ME3 | Q16798 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25228640 | 0.88 | HRH3 (0.46) | HRH3KDM4ESMN1; SMN2DRD4HTR7 | |
| SCHEMBL22644621 | 0.84 | HRH3 (0.43) | HRH3DRD4DRD2MEN1KMT2A | |
| SCHEMBL25279466 | 0.84 | ALDH1A1 (0.47) | HRH3MAPTGAAALDH1A1DRD4 | |
| SCHEMBL22644667 | 0.83 | DRD4 (0.45) | HRH3DRD4MEN1KMT2A | |
| SCHEMBL22638135 | 0.82 | HRH3 (0.54) | HRH3MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL29749314 | 0.81 | HRH3 (0.42) | HRH3DRD4MEN1KMT2A | |
| SCHEMBL22644705 | 0.81 | DRD4 (0.41) | HRH3MAPTKDM4EALDH1A1DRD4 | |
| SCHEMBL22638129 | 0.81 | HRH3 (0.41) | HRH3DRD4DRD2KMT2A | |
| SCHEMBL29749581 | 0.80 | DRD4 (0.40) | HRH3MAPTKDM4EALDH1A1DRD4 | |
| SCHEMBL13139591 | 0.80 | HRH3 (0.51) | HRH3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325708-B2 | Adenosine 2 receptor antagonists | NEKTAR THERAPEUTICS (US) | 2025-06-10 | — | — | US | disclosed |
| US-20220235056-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | NEKTAR THERAPEUTICS | 2022-07-28 | — | — | US | disclosed |
| WO-2020227156-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | NEKTAR THERAPEUTICS (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235056-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA3 | HRH3 1195/4885MAPT 4829/4885KDM4E 2170/4885 |
| US-12325708-B2 | Adenosine 2 receptor antagonists | ADORA2A, ADORA2B, ADORA3 | HRH3 1195/4885MAPT 4829/4885KDM4E 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.